Xeris Biopharma Files 8-K
Ticker: XERS · Form: 8-K · Filed: Dec 1, 2025 · CIK: 1867096
| Field | Detail |
|---|---|
| Company | Xeris Biopharma Holdings, Inc. (XERS) |
| Form Type | 8-K |
| Filed Date | Dec 1, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, sec-filing
TL;DR
Xeris Biopharma filed an 8-K on Dec 1, 2025. Standard disclosure stuff.
AI Summary
Xeris Biopharma Holdings, Inc. filed an 8-K on December 1, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific financial transactions or material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates Xeris Biopharma is making required disclosures to the SEC, which could include updates on financial status or significant business events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, with no immediate indication of significant negative events.
Key Players & Entities
- Xeris Biopharma Holdings, Inc. (company) — Registrant
- December 1, 2025 (date) — Date of Report
- 1375 West Fulton Street, Suite 1300 Chicago, Illinois 60607 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Xeris Biopharma Holdings, Inc.?
The filing is a Current Report on Form 8-K, intended to satisfy the filing obligations under Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically for Regulation FD Disclosure and Financial Statements and Exhibits.
On what date was this 8-K report filed and what is the earliest event date reported?
The report was filed as of December 1, 2025, and the date of the earliest event reported is also December 1, 2025.
What is the exact legal name and state of incorporation for the registrant?
The exact name is XERIS BIOPHARMA HOLDINGS, INC., and it is incorporated in Delaware.
What is the company's principal executive office address and phone number?
The principal executive offices are located at 1375 West Fulton Street, Suite 1300, Chicago, Illinois 60607, and the telephone number is (844) 445-5704.
What is Xeris Biopharma's SIC code and fiscal year end?
The Standard Industrial Classification (SIC) code is 2834 (Pharmaceutical Preparations), and the fiscal year ends on December 31st.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-12-01 07:00:50
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share XERS The Nasdaq Global Select
Filing Documents
- xers-20251201.htm (8-K) — 28KB
- exh991pressreleasedateddec.htm (EX-99.1) — 13KB
- picture1revised.jpg (GRAPHIC) — 4KB
- 0001867096-25-000161.txt ( ) — 168KB
- xers-20251201.xsd (EX-101.SCH) — 2KB
- xers-20251201_lab.xml (EX-101.LAB) — 22KB
- xers-20251201_pre.xml (EX-101.PRE) — 13KB
- xers-20251201_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On December 1, 2025, Xeris Biopharma Holdings, Inc. (the "Company") issued a press release announcing that the U.S. Patent and Trademark Office had issued a Notice of Allowance to the Company for its XP-8121 patent application. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 P ress Release , dated December 1, 2025 , issued by the Company 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 1, 2025 Xeris Biopharma Holdings, Inc. By: /s/ Steven M. Pieper Name: Steven M. Pieper Title: Chief Financial Officer